Skip to content

Eton Pharmaceuticals, Inc. ETON Uridine Triacetate — Other Commitment

Similar metrics at other companies

IBT
IBTAOther Commitment
$37.09M+28.4%
Inter Parfums logo
IPAROther Commitment
$1.31B+72.5%
Rayonier logo
RYNOther Commitment
$12.91M
BGC Group, Inc. logo
BGCOther Commitment
$0
Rumble, Inc. logo
RUMOther Commitment
$50M
Chicago Atlantic Real Estate Finance logo
REFIOther Commitment
$0

Other financials

Income statement

See full
Revenue$24.3M+40.4%
Gross profit$14.7M+49.4%
Operating income$2.4M+614%
Net income$1.6M+199%
EPS (diluted)$0.05+183%

Balance sheet

See full
Cash & equivalents$19.7M+12.9%
Total debt$31.3M+3.7%
Total equity$30.6M+25.2%
Total assets$97.7M+16.3%

Cash flow

See full
Operating cash flow$7.4M+254%
CapEx$75.0K
Free cash flow$7.3M+251%

Valuation

See full
Market cap$953.8M+162%
Enterprise value$965.4M+156%
P/S11×+3.4×

Profitability

See full
Gross margin54.8%-3.7pp
Operating margin-15.1%
Net margin-9.5%-2.7pp
FCF margin17.1%

Returns & leverage

See full
Return on equity-34.2%+0.9pp
Debt / equity-0.2×
Current ratio1.2×-0.8×

Where this comes from

Reported directly by Eton Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherCommitment.

The official record: Eton Pharmaceuticals, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eton Pharmaceuticals, Inc.'s uridine triacetate — other commitment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Eton Pharmaceuticals, Inc.'s uridine triacetate — other commitment?
Eton Pharmaceuticals, Inc. (ETON) reported uridine triacetate — other commitment of $1M in Q1 2026.
What does uridine triacetate — other commitment mean?
This metric captures miscellaneous contractual obligations or contingent liabilities associated with a specific product segment that fall outside of standard operating expenses or marketing rights payments. These commitments may include minimum purchase requirements, research and development funding obligations, or other long-term service agreements. Tracking these items is essential for understanding the total financial burden and potential future cash flow requirements tied to a specific asset.